Successful conversion surgery following chemotherapy with an immune checkpoint inhibitor in an older adult patient with stage IVB esophageal squamous cell carcinoma: a case report

被引:3
|
作者
Kawazoe, Tetsuro [1 ]
Ito, Shuhei [1 ]
Ohgaki, Kippei [1 ]
Fujinaka, Yoshihiko [1 ]
Funakoshi, Hiroki [1 ]
Otake, Akihiko [1 ]
Wang, Huanlin [1 ]
Morita, Kazutoyo [1 ]
Fushimi, Fumiyoshi [2 ]
Ikeda, Yoichi [1 ]
机构
[1] Kyushu Cent Hosp Mutual Aid Assoc Publ Sch Teacher, Dept Gastrointestinal Surg, 3 23 1 Shiobaru,Minami Ku, Fukuoka, Fukuoka 8158588, Japan
[2] Kyushu Cent Hosp Mutual Aid Assoc Publ Sch Teacher, Dept Pathol, Fukuoka, Japan
关键词
Esophageal squamous cell carcinoma; Conversion surgery; Immunotherapy; Older patients; GASTRIC-CANCER; PLUS; 5-FLUOROURACIL; ELDERLY-PATIENTS; PHASE-II; THERAPY; CHEMORADIOTHERAPY; IMMUNOTHERAPY; CISPLATIN;
D O I
10.1186/s40792-023-01634-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundChemotherapy and chemoradiotherapy are common treatments for esophageal squamous cell carcinoma with distant metastasis; however, the prognosis remains poor, and complete remission is difficult to achieve. Here, we report a case of an older adult patient with esophageal squamous cell carcinoma who underwent surgery following combined treatment of immunotherapy and chemotherapy and achieved pathological complete response.Case presentationAn 80-year-old woman presenting with difficulty swallowing was referred to our hospital. She was diagnosed with esophageal squamous cell carcinoma with distant metastasis of the lymph node at the dorsal side of the IVC and the left supraclavicular lymph node. She was treated with pembrolizumab, cisplatin, and 5-fluorouracil. After four pharmacotherapy courses, primary tumor and metastatic lymph node shrinkage was observed. The patient underwent thoracoscopic subtotal esophagectomy and regional lymph node dissection. The lymph node at the dorsal side of the IVC was not resected, and the left supraclavicular lymph node was removed. Histological examination revealed complete response with no residual tumor or lymph node metastasis. The patient had no recurrence 10 months postoperatively without adjuvant chemotherapy.ConclusionsConversion surgery following preoperative therapy, including immunotherapy, may be an effective treatment strategy for improving survival in patients with esophageal squamous cell carcinoma even among older adult patients.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
    He, Shengxiu
    Wang, Liang
    Sun, Yan
    Du, Huakun
    Yu, Xiaomin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [22] Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck
    Tanaka, Hideki
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Tanaka, Nobukazu
    Takeshita, Naohiro
    Onaga, Ryutaro
    Hoshi, Yuta
    Wada, Akihisa
    Sato, Masanobu
    Ueda, Yuri
    Tahara, Makoto
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [23] Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report
    Miura, Naoko
    Matsubara, Taichi
    Takamori, Shinkichi
    Haratake, Naoki
    Toyozawa, Ryo
    Yamaguchi, Masafumi
    Seto, Takashi
    Taguchi, Kenichi
    Takenoyama, Mitsuhiro
    OXFORD MEDICAL CASE REPORTS, 2020, (4-5):
  • [24] Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma
    Ratanasrimetha, Praveen
    Reddy, Vikas D.
    Kala, Jaya
    Tchakarov, Amanda
    Glass, William F.
    Msaouel, Pavlos
    Lin, Jamie S.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [25] Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment
    Xiaoyuan Wang
    Xiaodong Ling
    Changhong Wang
    Jinfeng Zhang
    Yingnan Yang
    Hao Jiang
    Yanzhong Xin
    Luquan Zhang
    Hao Liang
    Chengyuan Fang
    Dayong Zheng
    Jinhong Zhu
    Jianqun Ma
    Cancer Immunology, Immunotherapy, 2023, 72 : 1619 - 1631
  • [26] Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment
    Wang, Xiaoyuan
    Ling, Xiaodong
    Wang, Changhong
    Zhang, Jinfeng
    Yang, Yingnan
    Jiang, Hao
    Xin, Yanzhong
    Zhang, Luquan
    Liang, Hao
    Fang, Chengyuan
    Zheng, Dayong
    Zhu, Jinhong
    Ma, Jianqun
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (06) : 1619 - 1631
  • [27] Immune Checkpoint Inhibitor-induced Fatal Myositis in a Patient With Squamous Cell Carcinoma and a History of Thymoma
    Luecke, Eva
    Ganzert, Christine
    Vielhaber, Stefan
    Haybaeck, Johannes
    Jechorek, Doerthe
    Mawrin, Christian
    Schreiber, Jens
    CLINICAL LUNG CANCER, 2020, 21 (04) : E246 - E249
  • [28] Development of Spondyloarthritis Following Treatment With an Immune Checkpoint Inhibitor in a Patient With Metastatic Melanoma: A Case Report
    Meisels, Eden
    Shapiro, Justin
    Saltman, Alexandra
    JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 66 - 66
  • [29] Successful treatment of an elderly patient with lung squamous cell carcinoma by tislelizumab and chemotherapy: a case report with novel imaging findings
    Xu, Lufan
    Ma, Xinxin
    Yang, Yang
    Ding, Zhiqiang
    Luo, Yi
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [30] Immune-Checkpoint-Inhibitor induced fatal Myositis in a Patient with pulmonary Squamous Cell Carcinoma and a History of Thymic Carcinoma
    Luecke, E.
    Ganzert, C.
    Vielhaber, S.
    Haybaeck, J.
    Jechorek, D.
    Mawrin, C.
    Schreiber, J.
    PNEUMOLOGIE, 2020, 74 : S42 - S42